1. Home
  2. ISPR vs CDXS Comparison

ISPR vs CDXS Comparison

Compare ISPR & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ispire Technology Inc.

ISPR

Ispire Technology Inc.

N/A

Current Price

$3.10

Market Cap

175.8M

Sector

Health Care

ML Signal

N/A

Logo Codexis Inc.

CDXS

Codexis Inc.

N/A

Current Price

$1.28

Market Cap

141.8M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ISPR
CDXS
Founded
2010
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
175.8M
141.8M
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
ISPR
CDXS
Price
$3.10
$1.28
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.50
N/A
AVG Volume (30 Days)
62.5K
1.0M
Earning Date
02-06-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$118,506,875.00
$52,932,000.00
Revenue This Year
$11.60
$15.64
Revenue Next Year
$40.79
$5.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$1.22
52 Week High
$4.98
$4.51

Technical Indicators

Market Signals
Indicator
ISPR
CDXS
Relative Strength Index (RSI) 49.12 39.58
Support Level $3.28 $1.24
Resistance Level $3.87 $1.48
Average True Range (ATR) 0.32 0.13
MACD -0.03 -0.02
Stochastic Oscillator 27.66 15.04

Price Performance

Historical Comparison
ISPR
CDXS

About ISPR Ispire Technology Inc.

Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: